Wright Richard M. 4

4 · Celldex Therapeutics, Inc. · Filed Nov 17, 2025

Form 4

Period: 2025-11-13

Other

Transactions

Exercise/Conversion
Common Stock
2025-11-13$9.02/sh+6,876$61,997→ 27,709 total
Exercise/Conversion
Common Stock
2025-11-13$10.38/sh+26,672$276,855→ 54,381 total
Exercise/Conversion
Common Stock
2025-11-13$22.48/sh+15,750$354,060→ 70,131 total
Sale
Common Stock
2025-11-13$24.00/sh−49,298$1,183,177→ 20,833 total
Exercise/Conversion
Incentive Stock Option
2025-11-13−6,876→ 0 total
Exercise: $9.02Exp: 2028-06-13→ Common Stock (6,876 underlying)
Exercise/Conversion
Incentive Stock Option
2025-11-13−15,750→ 7,875 total
Exercise: $22.48Exp: 2032-06-16→ Common Stock (15,750 underlying)
Exercise/Conversion
Incentive Stock Option
2025-11-13−26,672→ 0 total
Exercise: $10.38Exp: 2030-06-18→ Common Stock (26,672 underlying)

Footnotes (4)

[F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.05 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
[F2]As of June 13, 2022, the option is fully vested.
[F3]As of June 18, 2024, the option is fully vested.
[F4]25% vested on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Documents

1 file